Vanda, after rejecting Future Pak offer, gets $466M takeout bid from Cycle Pharma

Vanda, after rejecting Future Pak offer, gets $466M takeout bid from Cycle Pharma

Source: 
Fierce Pharma
snippet: 

In recent months, Vanda Pharmaceuticals has been busy working to grow its commercial presence through its acquisition of Johnson & Johnson's Ponvory and its recent bipolar disorder approval for Fanapt. It seems the company's efforts are not going unnoticed.